Collection
Curated by Dr. Arthur B. Meyers From 4 sources across the library

Pediatric Musculoskeletal Imaging

items total cited expert statements Updated Nov 17, 2026
Start exploring
Try
Intelligent Search· answers come only from this collection · not medical advice
Content of this collection items

Radiation decisions in young children involve nuanced discussions of toxicities including pulmonary function, cardiac exposure, wound healing, and chest wall development, individualized case by case — Luke Pater, Clinical & Research Update: Sarcoma w/ Drs. Roshni Dasgupta, Joseph Pressey, Arthur Meyer, Luke Pater · 1:01:48

Clinical & Research Update: Sarcoma w/ Drs. Roshni Dasgupta, Joseph Pressey, Arthur Meyer, Luke Pater
This video presents a detailed clinical and research update on pediatric sarcomas from Cincinnati Children's, featuring a multidisciplinary team: with Drs. Roshni Dasgupta, Joseph Pressey, Arthur Meyers, & Luke Pater. It covers two complex
video1:06:24 · Sep 2026
Watch →
Pediatric Opacified Hemithorax: Differentiating Pneumonia from Ewing Sarcoma w/ Dr. Meyers & Pressey
This video presents a complex medical case of a 10-year-old international patient with an opacified hemithorax, initially thought to be pneumonia but unresponsive to antibiotics. Dr. Arthur Meyers discuss the imaging findings, including com
video0:37 · Nov 2026
Watch →

Inflammatory features on MRI include bone marrow edema, joint space inflammation, capsulitis, and enthesitis. Preliminary Definitions for Sacroiliac Joint Pathologies in the OMERACT Juvenile Idiopathic Arthritis Magnetic Resonance Imaging Score (OMERACT JAMRIS-SIJ)

Sacroiliac Joint Assessment2 items
Determination of Relative Weightings for Sacroiliac Joint Pathologies in the OMERACT Juvenile Arthritis Magnetic Resonance Imaging Sacroiliac Joint Score
This study aims to determine the relative weights (point value) of items of the juvenile idiopathic arthritis magnetic resonance imaging-sacroiliac joint scoring system (JAMRIS-SIJ). An adaptive multicriteria decision analysis was performed
article · Nov 2026
Read →
Preliminary Definitions for Sacroiliac Joint Pathologies in the OMERACT Juvenile Idiopathic Arthritis Magnetic Resonance Imaging Score (OMERACT JAMRIS-SIJ)
Objective: To develop definitions for the assessment of magnetic resonance imaging (MRI) pathologies of the sacroiliac joints (SIJ) in juvenile idiopathic arthritis. Methods: An Outcome Measures in Rheumatology (OMERACT) consensus-driven me
article · Nov 2026
Read →
Whole-Body MRI1 item
Reliability Assessment of the OMERACT Whole-Body Magnetic Resonance Imaging Scoring System for Juvenile Idiopathic Arthritis
Inter-reader reliability of a new scoring system for evaluating joint inflammation and enthesitis in whole body MRI (WBMRI) in juvenile idiopathic arthritis was tested. The scoring system grades 732 item-region combinations of bone marrow a
article · Nov 2026
Read →

Pediatric musculoskeletal POCUS curricula in rheumatology fellowship programs are limited due to availability of trained faculty and resources. Dissemination of a Pediatric Musculoskeletal POCUS Scoring System via Virtual Education: A Proof-of-Concept Study

POCUS Education and Training1 item
Dissemination of a Pediatric Musculoskeletal POCUS Scoring System via Virtual Education: A Proof-of-Concept Study
Point of care pediatric musculoskeletal POCUS scanning and scoring protocols for childhood arthritis have emerged in recent years. However, pediatric musculoskeletal POCUS curricula in rheumatology fellowship programs are limited due to ava
article · Nov 2026
Read →

Vega-Fernandez Lab
The goal of the Vega-Fernandez Lab is to improve outcomes for children with JIA by developing objective methods to detect joint inflammation and to guide personalized treatment decisions.
article · Nov 2026
Read →

Client Challenge
Client Challenge A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
article · Nov 2026
Read →
Patient and Family Resources
Patient and Family Resources | Cincinnati Children's Schedule an Appointment Directions International Billing Sign in to MyChart Ways to Help Donate Now Navigation Patients and Families Patients and Family Home Schedule an Appointment Servi
article · Oct 2026
Read →
Resources for Healthcare Professionals
Resources for Healthcare Professionals Schedule an Appointment Directions International Billing Sign in to MyChart Ways to Help Donate Now Navigation Patients and Families Patients and Family Home Schedule an Appointment Services and Specia
article · Oct 2026
Read →
Researchers, Cincinnati Children's Hospital Medical Center
We believe in science and compassion. Learn how our scientists conduct breakthrough research to improve the lives of children every day.
article · Oct 2026
Read →
Support Services | Cincinnati Children's Research Foundation
Support services help design grant proposals, manage data, comply with regulations, protect intellectual property and assist with commercialization. Read more.
article · Oct 2026
Read →
Newsroom
Cincinnati Children’s is dedicated to keeping families, healthcare professionals, and the news media informed with the latest updates, discoveries, and institutional milestones.
article · Oct 2026
Read →
Pdf Non Discrimination Statement.Pdf
%PDF-1.4 %���� 4 0 obj > endobj xref 4 104 0000000016 00000 n 0000002731 00000 n 0000002867 00000 n 0000002975 00000 n 0000004106 00000 n 0000004245 00000 n 0000004382 00000 n 0000005347 00000 n 0000006805 00000 n 0000006942 00000 n 0000007
article · Oct 2026
Read →

Clinical & Research Update: Sarcoma w/ Drs. Roshni Dasgupta, Joseph Pressey, Arthur Meyer, Luke Pater
Compressed-interval VDC/IE chemotherapy given every 2 weeks is now well proven to be of benefit over 3-week schedule for Ewing sarcoma
Joseph Pressey9:23
For chest wall sarcomas, the old adage of needing a rib above and a rib below for margins is not the case anymore; the goal is just to get negative margins if possible
Roshni Dasgupta11:23
When tumor is adherent to diaphragm or pericardium, you should not dissect these structures off the tumor because you don't know where the margin is; instead take a portion of the adherent structure with the tumor
Roshni Dasgupta12:18
Titanium rib reconstruction systems may need revision as the child grows, particularly during puberty with significant growth spurts
Roshni Dasgupta14:05
For Ewing sarcoma radiotherapy, treatment typically involves two phases: disease presentation volume and then more specific targeting of gross disease or positive margins
Luke Pater15:29
Protons are preferred over photons for focused boost volumes because they reduce low-dose exposure to non-target tissue beyond the target, though in lungs the benefit is compromised due to low-density tissue causing scatter
Luke Pater20:12
Small cell carcinoma of the ovary hypercalcemic type (SCCOHT) was originally described around 1980 in young adult women presenting with ovarian tumors with nondescript morphology, often associated with hypercalcemia
Joseph Pressey23:23
SCCOHT tumors are actually malignant rhabdoid tumors; some have postulated they should be called malignant rhabdoid tumor of the ovary
Joseph Pressey23:47
In 2014, three labs simultaneously identified SMARCA4 mutation (usually single nucleotide variant) as the underlying genetic defect in SCCOHT
Joseph Pressey24:06
SMARCA4 encodes BRG1 and its loss unifies all SCCOHT tumors; like Ewing sarcoma, these tumors have very low tumor mutational burden with SMARCA4 usually the only mutation found
Joseph Pressey24:40
Many SCCOHT patients enter the OR without this diagnosis in the differential; they are usually thought to be germ cell tumors, resulting in incomplete initial surgery
Joseph Pressey26:39
SCCOHT is a chemo-sensitive tumor but only transiently so; it is very important to start intensive systemic chemotherapy quickly rather than sending patients back for immediate second-look operation
Joseph Pressey27:00
The VPCBAE regimen (vinorelbine, cisplatin, cyclophosphamide, bleomycin, doxorubicin, etoposide) with all six agents given every 21-day cycle is very intensive toxic therapy requiring meticulous supportive care
Joseph Pressey27:20
Four cycles of VPCBAE induction chemotherapy are given prior to second-look operation for SCCOHT; patients with measurable disease after initial surgery often respond well even by RECIST criteria
Joseph Pressey27:43
The 12-month-old SCCOHT patient is the youngest ever described with this tumor; the average age for diagnosis is 24 years
Joseph Pressey28:25
MRIs and PET scans are not great for detecting peritoneal disease and very small nodules (1mm); second-look surgery is necessary to identify disease that imaging cannot detect
Roshni Dasgupta29:18
For SCCOHT second-look surgery, laparoscopy is used initially to understand extent of disease and determine size of laparotomy incision needed; the operation is never done with laparoscopy alone
Roshni Dasgupta29:44
Complete cytoreduction for SCCOHT includes removing all visible disease, with particular attention to peritoneal reflection in pouch of Douglas and surface of rectum where tumor can hide after spill
Roshni Dasgupta30:40
HIPEC in pediatric patients requires a multidisciplinary team experienced in this procedure; it is not the same as adult HIPEC
Roshni Dasgupta32:25
HIPEC protocol includes preoperative hyperhydration (1-2x maintenance fluids), warming abdomen to 42°C, cisplatin given in 2/3 dose initially and 1/3 at 45 minutes, continuous shaking for 90-minute dwell time, sodium thiosulfate infusion at 30 minutes to scavenge cisplatin, and 4-5L washout
Roshni Dasgupta32:59
Post-HIPEC patients receive 24 hours of hyperhydration in ICU; main counseled toxicities are ileus and kidney function issues, though the Cincinnati protocol has not seen significant renal toxicity
Roshni Dasgupta34:49
SCCOHT patients can resume next cycle of chemotherapy 4-7 days postoperatively after HIPEC once bowel function recovers
Roshni Dasgupta35:50
Maintaining interval compression as dense as possible (7-8 days to resume chemotherapy post-HIPEC) is very important to continue killing residual tumor cells
Joseph Pressey36:06
SCCOHT treatment uses 6 cycles of VPCBAE (usually 4 induction, 2 adjuvant); some stage 1 patients or those with considerable toxicity (especially renal) have stopped after 5 cycles to get to transplant in good health
Joseph Pressey36:39
Cincinnati uses busulfan-thiotepa conditioning for autologous stem cell transplant in SCCOHT, which is more toxic than the carboplatin-based regimen used by the French consortium but complements VPCBAE better with heavy alkylator exposure
Joseph Pressey37:08
Approximately 43% of SCCOHT patients carry germline SMARCA4 mutations; in Cincinnati's last 20 patients, 8 had germline SMARCA4 (40%)
Joseph Pressey37:56
For SCCOHT patients with germline SMARCA4, contralateral salpingo-oophorectomy should be performed at second-look operation because it would be nearly impossible to treat a metachronous SCCOHT tumor a second time with intensive therapy
Joseph Pressey38:21
Germline SMARCA4 mutations have been found in older SCCOHT patients in their late 30s with no prior personal or family history of cancer; all patients should be tested regardless of family history
Joseph Pressey38:55
Hysterectomy should be considered for germline SMARCA4 carriers due to risk of SMARCA4-deficient uterine sarcoma, which peaks around age 50 (later than SCCOHT which peaks at 23-24 years)
Joseph Pressey39:16
Two patients who survived SCCOHT developed metachronous SCCOHT tumors in the contralateral ovary and subsequently died, demonstrating this is a real risk not worth taking
Joseph Pressey39:37
GCMD Library — Curated collection · summaries prepared automatically from the recordings · educational content, not medical advice
Start the course
We remember your choice for this collection.
Follow this collection We'll email you when something new is added to Pediatric Musculoskeletal Imaging — the new recordings themselves, with links. Nothing when nothing is added; every email has an unsubscribe link.